"Breast Cancer Liquid Biopsy Market – Industry Trends and Forecast to 2030
Global Breast Cancer Liquid Biopsy Market, By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories) - Industry Trends and Forecast to 2030.
Data Bridge Market Research analyzes that the global breast cancer liquid biopsy market which was USD 278.07 million in 2022, would rocket up to USD 1,465.33 million by 2030, and is expected to undergo a CAGR of 23.09% during the forecast period.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-market
Breast cancer liquid biopsy refers to the use of liquid biopsy techniques specifically for the detection and monitoring of breast cancer. It involves the analysis of biomarkers present in bodily fluids, typically blood, to gain insights into the presence of breast cancer, monitor disease progression, assess treatment response, and identify specific genetic mutations or alterations associated with the disease.
**Segments**
- On the basis of biomarker, the Breast Cancer Liquid Biopsy Market can be segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and other biomarkers. Among these, CTCs are the most commonly used biomarkers in liquid biopsy for breast cancer, allowing for real-time monitoring of cancer progression and treatment response. ctDNA is also gaining traction due to its ability to detect genetic mutations in the tumor, guiding personalized treatment strategies. EVs are emerging as a promising biomarker due to their role in intercellular communication and information transfer.
- From the perspective of end user, the market can be categorized into hospitals, diagnostic laboratories, academic and research institutions, and others. Hospitals hold a significant share in the breast cancer liquid biopsy market as they are the primary point of care for cancer patients. Diagnostic laboratories are crucial for processing and analyzing liquid biopsy samples efficiently. Academic and research institutions play a key role in advancing the technology and understanding the clinical utility of liquid biopsy in breast cancer.
**Market Players**
- Some of the key market players in the global Breast Cancer Liquid Biopsy Market include Guardant Health, Inc., F. Hoffmann-La Roche Ltd, Qiagen, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Thermo Fisher Scientific Inc., Genomic Health, Inc., Illumina, Inc., and Cynvenio Biosystems, Inc. These companies are actively involved in research and development activities to enhance the sensitivity and specificity of liquid biopsy tests for breast cancer diagnosis and monitoring. Strategic collaborations, partnerships, and acquisitions are common strategies adopted by these market players to expand their product offerings and geographical presence.
https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-marketThe global Breast Cancer Liquid Biopsy Market is witnessing significant growth driven by advancements in precision medicine and the increasing adoption of non-invasive diagnostic techniques. Liquid biopsy, especially in breast cancer, offers a less invasive and more accessible method for monitoring disease progression, treatment response, and detecting genetic mutations. The segmentation based on biomarkers reflects the diverse ways in which liquid biopsy can provide valuable insights into the disease. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) each offer unique advantages in terms of real-time monitoring, genetic mutation detection, and intercellular communication, respectively. As research continues to explore the clinical utility of these biomarkers, the market is expected to witness further expansion.
From the end user perspective, the segmentation highlights the different stakeholders involved in the adoption and implementation of breast cancer liquid biopsy. Hospitals emerge as key end users due to their central role in cancer care, providing a hub for diagnosis, treatment, and monitoring. Diagnostic laboratories play a crucial role in processing and analyzing liquid biopsy samples efficiently, ensuring accurate and timely results. Academic and research institutions contribute to the advancement of the technology by conducting studies, clinical trials, and validating the clinical utility of liquid biopsy in breast cancer. The involvement of these diverse end users underscores the collaborative nature of advancing liquid biopsy techniques in clinical practice.
Market players in the global Breast Cancer Liquid Biopsy Market are actively engaged in research and development efforts to enhance the sensitivity and specificity of liquid biopsy tests. Companies such as Guardant Health, F. Hoffmann-La Roche, Qiagen, and Illumina are at the forefront of innovation, constantly seeking to improve the accuracy and reliability of liquid biopsy for breast cancer diagnosis and monitoring. Strategic collaborations, partnerships, and acquisitions are common strategies employed by these market players to leverage complementary expertise, expand product offerings, and strengthen their market position. With continued investments in technological advancements and clinical validation studies, the market is poised for sustained growth and innovation in the coming years**Segments:**
- **Biomarkers**: The Breast Cancer Liquid Biopsy Market segmentation based on biomarkers includes circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and other biomarkers. CTCs are widely used for real-time monitoring of cancer progression and treatment response. ctDNA is gaining popularity for detecting genetic mutations, guiding personalized treatment strategies. EVs are emerging as a promising biomarker due to their role in intercellular communication.
- **End Users**: From an end-user perspective, the market can be segmented into hospitals, diagnostic laboratories, academic and research institutions, and others. Hospitals are crucial in cancer care, serving as the primary point of care. Diagnostic laboratories are essential for processing and analyzing liquid biopsy samples efficiently. Academic and research institutions contribute to advancing technology and understanding the clinical utility of liquid biopsy in breast cancer.
**Global Breast Cancer Liquid Biopsy Market, By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories) - Industry Trends and Forecast to 2030:**
- Guardant Health, F. Hoffmann-La Roche, Qiagen, Bio-Rad Laboratories, and other key
The Breast Cancer Liquid Biopsy market research report displays a comprehensive study on production capacity, consumption, import and export for all the major regions across the globe. The target audience considered for this market study mainly consists of Key consulting companies advisors, Large, medium, and small-sized enterprises, Venture capitalists, Value-added resellers (VARs), Third-party knowledge providers, Investment bankers, and Investors. This global market analysis report is the believable source for gaining the market research that will exponentially accelerate the business growth. The top notch Breast Cancer Liquid Biopsy market report is the best option to acquire a professional in-depth study on the current state for the market.
Table of Contents: Breast Cancer Liquid Biopsy Market
1 Introduction
2 Global Breast Cancer Liquid Biopsy Market Segmentation
3 Executive Summary
4 Premium Insight
5 Market Overview
6 Breast Cancer Liquid Biopsy Market, by Product Type
7 Breast Cancer Liquid Biopsy Market, by Modality
8 Breast Cancer Liquid Biopsy Market, by Type
9 Breast Cancer Liquid Biopsy Market, by Mode
10 Breast Cancer Liquid Biopsy Market, by End User
12 Breast Cancer Liquid Biopsy Market, by Geography
12 Breast Cancer Liquid Biopsy Market, Company Landscape
13 Swot Analysis
14 Company Profiles
Countries Studied:
- North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Browse Trending Reports:
Scars Treatment Market
Atomic Force Microscope Afm Market
Network Slicing Market
Hypodermic Needles Market
Multivendor Atm Software Market
Hexane Market
Hemato Oncology Testing Market
Onchocerciasis Treatment Market
Table Linen Market
Fiber Optic Connector In Telecom Market
Ion Milling System Market
Regular Slotted Container Market
Aesthetic Injectables Market
Network Management Systems Market
Cloud Migration Market
Intelligent Humidifiers Market
Pediatric Dental Crown Market
Twist Dispensing Closures Market
Patient Engagement Technology Market
Personalized Retail Nutrition And Wellness Market
Meter Sockets Market
Kraft Pouch Market
Industrial Batteries Market
Food Grade Nitrogen Gas Market
Dental Scaling Units Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
